Matches in Wikidata for { <http://www.wikidata.org/entity/Q59334594> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q59334594 description "article scientifique publié en 2018" @default.
- Q59334594 description "im November 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q59334594 description "wetenschappelijk artikel" @default.
- Q59334594 description "наукова стаття, опублікована в листопаді 2018" @default.
- Q59334594 name "1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials" @default.
- Q59334594 name "1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials" @default.
- Q59334594 type Item @default.
- Q59334594 label "1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials" @default.
- Q59334594 label "1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials" @default.
- Q59334594 prefLabel "1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials" @default.
- Q59334594 prefLabel "1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials" @default.
- Q59334594 P1433 Q59334594-8EDCBD9B-83B7-4BB4-9332-A970744F9B7E @default.
- Q59334594 P1476 Q59334594-B48C7CE8-58AA-4CEF-ABD1-8DB8026F70AA @default.
- Q59334594 P2093 Q59334594-1258ADF1-64F5-4531-A3B7-E16FCE25864D @default.
- Q59334594 P2093 Q59334594-2C7CFBB1-2945-481F-8D3B-9E0CBFCA6393 @default.
- Q59334594 P2093 Q59334594-40D16E83-2F73-42B9-BE48-27AF455F3130 @default.
- Q59334594 P2093 Q59334594-7A0534D0-5A29-4138-BF2F-EDD84529263B @default.
- Q59334594 P2093 Q59334594-9B8595D0-0456-407A-AE6F-6BC048B4AE1C @default.
- Q59334594 P2093 Q59334594-B03B162F-692F-44DB-B8CF-06E8BAD4322A @default.
- Q59334594 P275 Q59334594-536194a1-bc09-4a5f-89e8-5f987dc03bb2 @default.
- Q59334594 P304 Q59334594-509E58A7-46EE-4E8C-B4A3-D059441C73A6 @default.
- Q59334594 P31 Q59334594-0D629038-AC45-445B-8E07-97C5FD3D89EB @default.
- Q59334594 P356 Q59334594-E463BA5D-D73E-4B4C-9C9D-E2E7C224D522 @default.
- Q59334594 P433 Q59334594-74F21502-F87B-432D-92C1-6E83302F086E @default.
- Q59334594 P478 Q59334594-70E0480A-3DD5-4F29-91CB-911657EC8C0D @default.
- Q59334594 P50 Q59334594-6BDB246D-F18E-41E1-B956-A8C455D57848 @default.
- Q59334594 P50 Q59334594-BAD93F6D-979F-45CB-824C-6CF93965380D @default.
- Q59334594 P50 Q59334594-D90DBBCF-1E3F-4DC3-A685-05891BFFD201 @default.
- Q59334594 P577 Q59334594-8C38001B-510F-4510-A28B-B3567324B364 @default.
- Q59334594 P6216 Q59334594-0619a6af-6cb0-4133-be61-7632add048d4 @default.
- Q59334594 P921 Q59334594-007C8F9B-669A-46A2-9AC9-C7FD4D2FEF42 @default.
- Q59334594 P921 Q59334594-C23729F4-1CE5-4B9D-8CCF-E871E926CDF1 @default.
- Q59334594 P921 Q59334594-C7EDC83C-E604-4D2A-91E2-6D659043E782 @default.
- Q59334594 P932 Q59334594-12BB740C-9836-412A-8B0B-16D1ED0B90CB @default.
- Q59334594 P356 OFY210.1621 @default.
- Q59334594 P1433 Q27725953 @default.
- Q59334594 P1476 "1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials" @default.
- Q59334594 P2093 "Federico Mensa" @default.
- Q59334594 P2093 "Karine Lacombe" @default.
- Q59334594 P2093 "Roger Trinh" @default.
- Q59334594 P2093 "Ruth Soto-Malave" @default.
- Q59334594 P2093 "Sanjay R Bhagani" @default.
- Q59334594 P2093 "Stanley Wang" @default.
- Q59334594 P275 Q24082749 @default.
- Q59334594 P304 "S569-S570" @default.
- Q59334594 P31 Q13442814 @default.
- Q59334594 P356 "10.1093/OFID/OFY210.1621" @default.
- Q59334594 P433 "suppl_1" @default.
- Q59334594 P478 "5" @default.
- Q59334594 P50 Q47006499 @default.
- Q59334594 P50 Q66752326 @default.
- Q59334594 P50 Q87418404 @default.
- Q59334594 P577 "2018-11-01T00:00:00Z" @default.
- Q59334594 P6216 Q50423863 @default.
- Q59334594 P921 Q42824827 @default.
- Q59334594 P921 Q55779873 @default.
- Q59334594 P921 Q708693 @default.
- Q59334594 P932 "6252827" @default.